Redeye raises its base case following Xspray’s announcement that XS003 has achieved bioequivalence w...
Redeye updates its estimates following Waystream’s Q2 report last week.
Q2 EBITDA of NOK 7m StrongPoint showed a positive development with sales +18% y-o-y, mostly driven b...
Market headwinds worsened by accounting effects Careium delivered soft sales in Q2, with organic gro...
Redeye updates its Base Case and forecasts for Lime following the Q2 report.
Q2 results Coor continued the positive trend and delivered better earnings than expected in Q2 while...
Scanfil buys MB Elettronica which has 4 factories in Italy.
Q2 results Organic growth improved and was positive y-o-y, but earnings in service-related units wei...
Q2e: FX headwinds, but continued strong margins We expect Nolato to report Q2 net sales of SEK 2,345...
Plejd rapporterade för andra kvartalet 2025 en nettoomsättning om 210,7 MSEK (146,2), motsvarande en...
The organic CER growth at -11% is a major negative surprise, and the H1 organic CER growth is 1%.
Redeye comments on Alligator Bioscience's second quarter report 2025.
We estimate Q2 2025 pre-tax profit of DKK 69m, down DKK 36m (34%) y/y.
- Q2 sales 8% below our ests. at SEK 202m, for -9% org.
- Q2: Sales 6% above, EBITDA NOK 7m vs ABGSCe NOK 3m - Positive development in projects - Only minor...
Redeye comments on Lime’s Q2 report, showing solid underlying numbers despite sales being hurt by so...
Redeye updates its production estimates ahead of Arise's Q2 report on Friday next week (18 July).
Incap has guided for net sales to grow by 0-20% for 2025.
- We cut '25e-'27e adj. EBITA by 5-4% - Pressure on demand and hourly prices - NTM EV/EBITA below 7x...
- Earnings naturally hedged - Potential to generate order intake above the historical average - NTM ...
